NewsRoom Articles - Page 110 of 153 - PsychedelicNewsWire (PNW)

TuesdayDec 22, 2020 3:15 pm

Psychedelic Company Carrying Out Trials for Coronavirus Treatment

The announcement of the coronavirus vaccines from Pfizer, Moderna and Oxford is a hopeful sign for many. Nonetheless, there’s still a lot that we do not know about the coronavirus infection. However, researchers continue to work diligently to learn more about the SARS-CoV-2 virus, which causes the infection. While the vaccines that have been made are not 100% effective, they are effective enough to help achieve herd immunity, which will assist in efforts to contain the virus that is spreading rapidly, overwhelming health-care facilities and killing without mercy. Many private firms are looking into coronavirus treatments, including Revive Therapeutics (CSE:…

MondayDec 21, 2020 11:00 am

Pure Extracts Technologies Corp. (CSE: PULL) Names Key Advisor; Targets Development of Mushroom Formulations

Pure Extracts is working with Dr. Alexander MacGregor on development of mushroom products, including some combined with CBD. MacGregor is widely renowned as pharmaceutical science inventor, expert in pharmaceutical technology and novel drug-delivery systems. Pure Extracts is focused on expansion of its cannabis extraction business model to include mushroom formulations. Pure Extracts Technologies (CSE: PULL) has established a key collaborative relationship with an expert in translating pharmaceutical knowledge into a sustainable business. The plant-based extraction company, which is focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is working closely with Dr. Alexander MacGregor on developing quality cannabis…

MondayDec 21, 2020 10:00 am

UK Government Expects Huge Return From Psychedelic Investment

Angel CoFund, an investor backed by the UK government, holds a 5.5% stake in Small Pharma, a London-based neuropharmaceutical company. Small Pharma recently announced that it planned to list the firm on the Toronto Stock Exchange through Unilock Capital Corp, a Canadian capital pool, via reverse takeover. The company’s objective is to raise $ 15.6 million, an equivalent of C$20 million, which will finance the clinical trial of dimethyltryptamine/DMT-assisted therapy treatment for depression. DMT is an active compound found in ayahuasca, an Amazonian psychedelic brew. While Angel CoFund is a privately run organization, it is funded by a £100 million…

FridayDec 18, 2020 4:00 pm

How Retired Pro Athletes Use Psychedelics

Former UFC fighters Dean Lister and Ian McCall, former NHL player Daniel Carcillo and former NFL player Kerry Rhodes are a few well-known athletes who current using plant medicines such as psilocybin mushrooms and ayahuasca to help manage brain trauma symptoms and heal their PTSD. Carcillo suffered from mental and physical trauma following the effects of repeated concussions after retiring from the NHL. It wouldn’t have been easy to spot though, given that from the outside, he seemed to have it all — from a successful career to a comfortable home and a lovely family. CTE, or chronic traumatic encephalopathy,…

ThursdayDec 17, 2020 1:50 pm

Pure Extract Technologies (CSE: PULL) Provides Update on Expansion into Functional Mushrooms Sector

Pure Extracts Technologies recently provided update into its expansion into functional mushrooms sector Functional mushrooms have enjoyed surge in popularity as of late, are increasingly being used in wide variety of healthcare, pharmaceutical products Functional mushrooms sector is expected to grow to annual market value of $34.4 billion by 2024 Pure Extracts plans to develop high bio-available products derived from functional mushrooms through use of its proprietary extraction processes Company also set to launch its own branded functional mushrooms-based products under ‘Pure Mushrooms’ brand from Q1 2021 onwards and has signed a LOI with the PURICA(TM) brand of mushroom wellness…

ThursdayDec 17, 2020 1:30 pm

Functional vs. Psilocybin Mushrooms: A Guide to Investing

As psychedelics move into mainstream media, the attention on substances such as psilocybin and MDMA grows. Chances are good that you’ve heard of psilocybin mushrooms, but did you know that an entirely different category of mushrooms exists, nonpsychedelics that are called functional mushrooms. Examples of these mushrooms include reishi, chaga and lion’s mane. These two growing markets can both be considered as potential investment opportunities. Below, we look at their differences and examine the potential for growth and profit for investors. Wellness space or media spotlight: Which is better? Magic mushrooms are hallucinogenic mushrooms that have the psychoactive component psilocybin.…

WednesdayDec 16, 2020 3:00 pm

Canadian Government to Allow Therapists to Use Psilocybin Mushrooms

Canada’s Health Minister Patter Hajdu recently stated that the country would allow some health-care professionals to both consume and possess psilocybin mushrooms. The aim of this move is to provide a way that health-care professionals can better understand and recognize how to treat the increasing number of patients who have been allowed to use the psychedelic. This is the health ministry’s first public response to the psilocybin-use pending applications by therapists. Over the summer, the health ministry allowed a limited number of patients to use psilocybin mushrooms as part of their psychotherapy in their end-of-life care. However, ministry of health…

WednesdayDec 16, 2020 12:42 pm

Traditional Chinese Medicine Takes Root in Western Culture with Rritual Superfoods Product Line

Rritual Superfoods, Inc., is a budding new superfood developer aiming to improve people’s overall wellness with purposefully designed elixirs pairing acclaimed mushroom varieties with adaptogenic herbs The company was organized earlier this year and has launched three initial product varieties using the Chaga, Reishi and Lion’s Mane mushrooms in tandem with adaptogenic roots plus herbal spices and natural whole foods Rritual’s products are designed to help users combat stress, strengthen their immune systems and enhance their mental clarity The nascent functional mushroom market is expected to grow with a CAGR of 8.04 percent between 2019 and 2024, according to Mordor…

TuesdayDec 15, 2020 3:15 pm

Could Prejudices Be Holding Us Back from Accepting Psychedelics as Mental Health Treatment?

Current pharmaceutical drugs for depression seem to be causing more harm than good to their users, with some patients developing a resistance to treatments while others become dependent on the treatments. This may be a reason for the increase in interest in the use of psychedelic drugs as alternative and potentially safer treatments for depression and other mental health conditions. The first time psychedelics were studied as a potential mental-health treatment was several decades ago, when researchers studied the therapeutic potential of LSD. However, as decades passed and various national and international drug policies were implemented, further research exploring the…

TuesdayDec 15, 2020 1:41 pm

Cybin Inc. (NEO: CYBN) on Right Path; Johns Hopkins Study Shows Psilocybin Positive Impact on Major Depression

Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depression Most participants reported improvements; half experienced remission after only four weeks As an early entrant in the field, Cybin looks well placed to capitalize on growing traction that psychedelics gain as potential treatment of mental health conditions Only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in depressive symptoms in adults with major depression, according to recent research conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry” (https://ibn.fm/AM1Ww). As a leading life sciences company focused on psychedelic drug development, Cybin…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000